Valeant

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return in the last five years is 131.9%. But there is no question some big-name stocks performed better than others along the way. Valeant’s Downfall: One...

Bausch Health Companies Inc (NYSE: BHC) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals roughly a year ago, announced Tuesday it's using $100 million in cash from...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) peaked north of $250 per share in 2015, but by 2017 they dropped to a single digit. Needless to say, this represented a challenging time for the company.   But since bottoming at $8.31 per share this year, the company has made "great...

Analysts at Cantor Fitzgerald turned incrementally bullish on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the once-troubled pharmaceutical company is showing signs of sustaining momentum. Cantor Fitzgerald's Louise Chen maintains an Overweight rating on Valeant's stock with a price...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) gained more than 3.5 percent early Thursday morning after the company announced the sale of one of its business units. Valeant has agreed to sell its iNova Pharmaceuticals business for $930 million to a group advised and managed by major...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) rose about 14 percent early Tuesday morning after the troubled pharmaceutical company reported an encouraging first quarter earnings report and guidance raise. Valeant reported a first quarter GAAP earnings per share of $1.79, which marks an...

Troubled pharmaceutical company Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Friday pricing for its SILIQ (brodalumab) injection. What Is SILIQ? The U.S. Food and Drug Administration approved the Biologics License Application for SILIQ, which is a monoclonal antibody that targets the...

There has been much talk of Bill Ackman losing his magic touch over his disastrous bets on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), where he lost $4.6 billion, and his infamous short on Herbalife Ltd.(NYSE: HLF), which has gained 22 percent on the year and sparked a movie release on his...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s refinancing announcement on Tuesday shouldn't be celebrated by investors, at least according to Gadfly's Max Nisen. Nisen noted Valeant's "financial wizardry" doesn't address Valeant's long-term $30 billion debt load although it may ease short-term...

Billionaire investor Bill Ackman cut his losses in Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock so now is the time for both the company and hedge fund manager to move on. According to a Bloomberg report, Valeant's path forward is difficult and characterized by the company having less money...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plummeted 11 percent Tuesday after notable hedge fund manager Bill Ackman exited his large position of the pharmaceutical company at a loss that could be in the billions of dollars. Valeant's stock peaked north of $250 per share in 2015 and on...

Bill Ackman's Pershing Square released an annual update presentation for investors and the public. One of Ackman's most notable holdings is Valeant Pharmaceuticals Intl Inc (NYSE: VRX), the troubled pharmaceutical company that was plagued with controversies and concerns over its debt...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced an agreement to sell its CeraVe, AcneFree and AMBI Skincare brands to L'Oreal SA (ADR) (OTC: LRLCY) for $1.3 billion. According to Gadfly's Andrea Felsted, the $1.3 billion price tag on the deal is worth it for the France-based consumer goods...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) soared higher by more than 13 percent Tuesday morning after the company agreed to sell multiple business units as part of an ongoing initiative to pay down its debt load, which has some Wall Street analysts deeply concerned. Valeant has agreed...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Monday that three senior executives will be leaving the company. The executives that will be leaving the company include: Valeant's ex CFO Rob Rosiello, who stepped down in August but remained with the company since. Ari...